Abstract
The differentiation between radiation-induced changes and tumor recurrence is a major pitfall of magnetic resonance imaging, which can be overcome by the use of PET. Although amino-acid PET tracers showed several advantages over F-fluorodeoxyglucose in neurooncology, studies comparing these 2 types of radiopharmaceuticals in previously irradiated brain metastases are lacking. Here, we demonstrated a mismatch between 3,4-dihydroxy-6-[F]-fluoro-L-phenylalanine (F-DOPA) and FDG in the first report of a previously irradiated brain metastasis undergoing a longitudinal evaluation by sequential double tracer PET imaging.
Original language | English |
---|---|
Pages (from-to) | 557-558 |
Number of pages | 2 |
Journal | Clinical Nuclear Medicine |
Volume | 45 |
Issue number | 7 |
DOIs | |
Publication status | Published - Jul 2020 |
Keywords
- Brain Neoplasms/diagnostic imaging
- Diagnosis, Differential
- Dihydroxyphenylalanine/analogs & derivatives
- Female
- Fluorodeoxyglucose F18
- Humans
- Magnetic Resonance Imaging
- Male
- Neoplasms, Radiation-Induced/diagnostic imaging
- Positron-Emission Tomography
- Radiosurgery/adverse effects